84
Participants
Start Date
March 31, 2010
Primary Completion Date
April 30, 2012
Study Completion Date
April 30, 2012
BG00002 (natalizumab)
300 mg intravenous injection every 4 weeks
interferon beta-1a
44 mcg subcutaneous injection 3 times per week
glatiramer acetate
20 mg subcutaneous injection once daily
Research Site, Cullman
Research Site, Phoenix
Research Site, Fort Collins
Research Site, Maitland
Research Site, St. Petersburg
Research Site, Tampa
Research Site, Atlanta
Research Site, Lexington
Research Site, New Orleans
Research Site, Detroit
Research Site, Patchogue
Research Site, Charlotte
Research Site, Akron
Research Site, Franklin
Research Site, Knoxville
Research Site, Round Rock
Research Site, Norfolk
Research Site, Kirkland
Research Site, Morgantown
Research Site, Fitzroy
Research Site, Gatineau
Research Site, Pardubice
Research Site, Tampere
Research Site, Strasbourg
Research Site, Esztergom
Research Site, Budapest
Research Site, Nyíregyháza
Research Site, Catania
Research Site, Napoli
Research Site, Rome
Research Site, Riga
Research Site, Bialystok
Research Site, Gdansk
Research Site, Lódz
Research Site, Ljubljana
Research Site, Barcelona
Research Site, Alicante
Research Site, Girona
Research Site, Madrid
Research Site, Santa Cruz de Tenerife
Research Site, Seville
Research Site, Mölndal
Lead Sponsor
Collaborators (1)
Elan Pharmaceuticals
INDUSTRY
Biogen
INDUSTRY